Beijing Strong Biotechnologies,Inc. researches, (300406) Fair Value & Analysis
Healthcare · CN · Market cap 6.7B CNY
Fair value as of: Jul 9, 2026
From 26 valuation models · updated 32 days ago
Share price +3.5% over the past month.
A solid business, but screening 39% overvalued on our models.
What matters now
- A high-quality business (quality 72/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case (¥8.91). The favourable scenario is already priced in.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
60‑month range ¥9.90 – ¥21.85 · fair‑value band ¥5.34 – ¥8.91 · the ¥11.75 price screens above the ¥7.12 fair value. Dashed = 300-day average. As of Jul 9, 2026.
Analysis
Beijing Strong Biotechnologies,Inc. researches, (300406) currently trades at ¥11.75, while our model-based Fair Value estimate is ¥7.12, implying the stock looks roughly 39.4% overvalued today. The Quality Score stands at 72/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Beijing Strong Biotechnologies,Inc. researches, generated revenue of 1.4B CNY at a net margin of 15.5%. Revenue grew 4.7% year over year. It earns a return on equity of 5.3%. Net debt stands at 524M CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥5.34 (bear case) to ¥8.91 (bull case); at ¥11.75, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 22% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside, at -39%, 300406 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Dividend Discount (¥13.60) versus Earnings-Based (¥2.44). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 70 · Market factors (momentum, volatility) 47
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Beijing Strong Biotechnologies,Inc. researches, develops, manufactures, and sells in-vitro diagnostics (IVD) products and services in China and internationally.
Full company description
Beijing Strong Biotechnologies,Inc. researches, develops, manufactures, and sells in-vitro diagnostics (IVD) products and services in China and internationally. The company offers biochemistry reagents, including liver, renal, lipid, cardiac, diabetes, special protein, tumor marker, pancreas, inorganic, inflammation, TDM, and other panels; and coagulation products, such as prothrombin time, activated partial thromboplastin time, thrombin time, and fibrinogen, as well as antithrombin III, von Willebrand factor antigen, protein S activity, protein C, lupus anticoagulant, fibrin degradation products, and d-dimer. It also provides blood grouping card comprising ABO blood type anti stereotype detection card, DiaClon ABD-confirmation, and DiaClon ABO/D+ reverse grouping for patients; and automatic coagulation analyzer, automatic biochemistry analyzer, fully automatic chemiluminescence immunoassay analyzer, and automated blood groupings analyzer. In addition, the company provides technology and document services. It sells its products under the GCELL and Beijing MDC brands. The company was founded in 2001 and is based in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Beijing Strong Biotechnologies,Inc. researches, reported revenue of ¥1.4B in FY2025 versus ¥1.6B in FY2021, a compound −4.1%/yr. Reported net income was ¥190M in FY2025, compounding −17.3%/yr from FY2021.
300406 screens 39% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 136 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $543.19 | $308.19 | -43% |
| Danaher Corporation DHR | $199.66 | $103.88 | -48% |
| WuXi AppTec Co 2359 | HK$160.70 | HK$125.20 | -22% |
| Lonza Group LONN | CHF 567.80 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $567.44 | $255.77 | -55% |
| Agilent Technologies, Inc A | $131.46 | $62.70 | -52% |
| Waters Corporation WAT | $368.98 | $121.96 | -67% |
| IQVIA Holdings IQV | $207.85 | $134.18 | -35% |
| Integrated Diagnostics Holdings IDHC | $0.0050 | $0.0053 | +5% |
| Illumina, Inc ILMN | $186.65 | $95.51 | -49% |
Compare Beijing Strong Biotechnologies,Inc. researches, with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Beijing Strong Biotechnologies,Inc. researches, (300406) overvalued or undervalued?
What is the fair value of 300406?
What is the quality score of 300406?
What is the revenue of Beijing Strong Biotechnologies,Inc. researches, (300406)?
What is the net profit margin of 300406?
Does Beijing Strong Biotechnologies,Inc. researches, pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Beijing Strong Biotechnologies,Inc. researches, and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.